Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan
Alimentary Pharmacology & Therapeutics · 2025-02 · 61 (3) · 524-537
DOI: 10.1111/apt.18406 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 22.11.2024. Verfasst von Shintaro Akiyama und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Janus Kinase Inhibitors, Piperidines, Pyrimidines. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan.
Aim
To compare the real‐world efficacy and safety of these three JAK inhibitors in UC.
Methods
This was a multicentre, retrospective study of patients with UC started on JAK inhibitors. The primary outcome was clinical remission at 10, 26 and 58 weeks, and at the most recent follow‐up. To compare the efficacy and safety among the JAK inhibitors, we created three matched cohorts (upadacitinib vs. filgotinib, tofacitinib vs. filgotinib and upadacitinib vs. tofacitinib) using propensity score matching.
Results
We identified 228 upadacitinib‐treated patients (median follow‐up 49 weeks; IQR 25–72), 215 filgotinib‐treated patients (follow‐up 56 weeks; IQR 17–82) and 159 tofacitinib‐treated patients (follow‐up 112 weeks; IQR 10–258). Clinical remission rates for upadacitinib, filgotinib and tofacitinib at the most recent follow‐up were 72.8%, 50.6% and 45.8%, respectively. Over 70% of the patients previously treated with other biologics or JAK inhibitors achieved clinical remission with upadacitinib. On multivariate analysis, the number of previous advanced therapies was inversely associated with the efficacy of filgotinib and tofacitinib. Comparative analysis showed that upadacitinib‐treated patients had higher efficacy and lower risk of discontinuation than patients treated with other JAK inhibitors. However, upadacitinib had a significant risk of acne.
Conclusions
Considering the particularly high efficacy of upadacitinib, even in patients with refractory UC, filgotinib or tofacitinib may be considered as an upfront JAK inhibitor before using upadacitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
- Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan.
- Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan.
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
ORCID-Profile: Shintaro Akiyama, Toshiyuki Sakurai, Shunichi Yanai, Masayuki Saruta, Toshimitsu Fujii
Zitieren
APA
Akiyama, S., Shimizu, H., Tamura, A., Yokoyama, K., Sakurai, T., Kobayashi, M., Eizuka, M., Yanai, S., Nomura, K., Shibuya, T., Takahara, M., Hiraoka, S., Sako, M., Yoshida, A., Tsuruta, K., Yoshioka, S., Koroku, M., Omori, T., Saruta, M., …, & Fujii, T. (2025). Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan. Alimentary Pharmacology & Therapeutics, 61(3), 524-537. https://doi.org/10.1111/apt.18406
Vancouver
Akiyama S, Shimizu H, Tamura A, Yokoyama K, Sakurai T, Kobayashi M, et al. Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan. Alimentary Pharmacology & Therapeutics. 2025;61(3):524-537. doi:10.1111/apt.18406
BibTeX
@article{Akiyama2025,
author = {Akiyama, Shintaro and Shimizu, Hiromichi and Tamura, Akiko and Yokoyama, Kaoru and Sakurai, Toshiyuki and Kobayashi, Mariko and Eizuka, Makoto and Yanai, Shunichi and Nomura, Kei and Shibuya, Tomoyoshi and Takahara, Masahiro and Hiraoka, Sakiko and Sako, Minako and Yoshida, Atsushi and Tsuruta, Kozo and Yoshioka, Shinichiro and Koroku, Miki and Omori, Teppei and Saruta, Masayuki and Matsumoto, Takayuki and Okamoto, Ryuichi and Tsuchiya, Kiichiro and Fujii, Toshimitsu},
title = {Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {61},
number = {3},
pages = {524--537},
doi = {10.1111/apt.18406}
}
EUVIMED